As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have enlarged exposure to rare disease therapeutics companies as the orphan drugs market sustains robust ...

Evidence-based medicine "Boy Wonder" Dr. Vinay Prasad was fired as CBER Director after less than three months on the job.

Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.

In a sweeping move to eliminate mercury exposure from vaccines, U.S. Department of Health and Human Services Secretary Robert ...

For University of Montana marketing researcher Jesse King, commercials – namely pharmaceutical advertisements – are intensely ...

Q2 2025 Earnings Call Transcript August 1, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Dr George Tidmarsh, a former pharmaceutical executive who joined the FDA this month, will take over Prasad’s role temporarily.

Recalls happen most every day, but some can be more impactful than others. These are the most major recalls in recent history ...